TIE2: Human TIE2, a receptor-like tyrosine kinase, tyrosine kinase domain, active and recombinant enzyme
TIE2 is a receptor-like tyrosine kinase expressed almost exclusively in endothelial cells and early hemopoietic cells and is required for the normal development of vascular structures during embryogenesis. In adult tissues a dual function for TIE2 involving both angiogenesis and vascular maintenance has been reported. TIE2 also plays an important role in tumour angiogenesis demonstrating the potential use of TIE2 expression as a novel marker of tumour vasculature. The p85 subunit of phosphatidylinositol 3-kinase (PI3-kinase) associates with TIE2 and this association confers functional lipid kinase activity. The activation of PI3-kinase and Akt may account for TIE2´s role in both embryonic vascular development and pathologic angiogenesis. Human TIE2 kinase domain, recombinantly expressed in insect cells and affinity-purified as fusion protein (active). Purity > 95% (SDS PAGE).
Size: 10 µg
Ordering information: shipped on dry ice
Product specific literature references:
Davis S, Aldrich TH, Yancopoulos GD et al. (1996) "Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning" Cell 87(7):1161-9
Suri C, Jones PF, Yancopoulos GD et al. (1996) "Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis" Cell 87(7):1171-80
Vikkula M, Boon LM, Carraway KL 3rd, Olsen BRet al. (1996) "Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2" Cell 87(7):1181-90
Maisonpierre PC, Suri C, Yancopoulos GD et al. (1997) "Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis" Science 277(5322):55-60
Wong AL, Haroon ZA, Peters KG (1997) "Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues" Circ Res. 81(4):567-74
Peters KG, Coogan A, Trogan E et al. (1998) "Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis" Br J Cancer 77(1):51-6
Kontos CD, Stauffer TP, Peters KG et al. (1998) "Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt" Mol Cell Biol. 18(7):4131-40
Jones N, Master Z, Dumont DJ et al. (1999) "Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration" J Biol Chem. 274(43):30896-905
Brown LF, Dezube BJ, Yancopoulos GD et al. (2000) "Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma" Am J Pathol. 156(6):2179-83
Hata K, Udagawa J, Miyazaki K et al. (2002) "Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer" Oncology 62(4):340-8
Niu XL, Peters KG, Kontos CD (2002) "Deletion of the carboxyl terminus of Tie2 enhances kinase activity, signaling, and function. Evidence for an autoinhibitory mechanism" J Biol Chem. 277(35):31768-73
Hughes DP, Marron MB, Brindle NP (2003) "The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2" Circ Res. 92(6):630-6
Arai F, Hirao A, Suda T et al. (2004) "Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche" Cell 118(2):149-61
Product Information
